Abstract: Neurofibromatosis type 1 is an autosomal dominant neurocutaneous disorder affecting 1 in 3000 births. This familial tumor predisposition syndrome is diagnosed clinically and affects the skin, bones, and nervous system. Malignant tumors can arise in childhood or adulthood and are the most common cause of mortality in this population. Early diagnosis and management led by a multidisciplinary team remains the standard of care, particularly in the management of optic pathway glioma. Emerging concepts in the genetic patterns of this condition have led to the introduction of new treatment modalities that target the mitogen-activated protein kinase and the mammalian target of rapamycin pathways. In this review, the role of the ophthalmologist and approach to screening for optic pathway glioma are outlined based on previous recommendations. Updates on choroidal involvement, as a diagnostic criterion, will also be discussed, further highlighting the pivotal role of the ophthalmologist in the diagnosis and management of this complex condition.
EPIDEMIOLOGY
Neurofibromatosis 1 is one of the most common genetic disorders with no sex or racial predilection. It occurs in approximately 1 in 3000 people. 3 Estimates of the prevalence of NF1 range from 1:2190 4 to 1:7800. 5 Some of the difficulties with accurate prevalence data for this condition may be due to ascertainment bias 6 partly because of the wide variability in the expression of the condition, whereby mild cases may escape study inclusion particularly in studies dependent on an affected individual coming to medical attention. 7 Reduced prevalence in later adulthood may be due to increased mortality seen in individuals with NF1 or to underascertainment of adult patients. 8 The physician Mark Akenside first recognized the disorder in 1768. Robert Smith, an Irish surgeon, published further details on the disease in 1849. However, it was the German pathologist Friedrich von Recklinghausen who is credited with its recognition in 1882. 1 
GENETICS AND PATHOPHYSIOLOGY
The inheritance of NF1 is autosomal dominant with 100% penetrance but highly variable expressivity. 1, 3, 9 Importantly, a high spontaneous mutation rate of up to 42% exists. 3 The NF1 gene is located on chromosome 17q11.2 and was cloned in 1990. It was originally cloned by the Wallace group 10 along with the Cawthon and Viskochil group. 11 It is an important tumor suppressor gene found throughout the nervous system. 12 The NF1 gene encodes the protein neurofibromin, which influences multiple signaling pathways affecting many cellular processes throughout the body. Importantly, it acts as a negative regulator of cell growth and proliferation.
2 Several pathways are thought to be involved in the development of tumors associated with NF1. Loss of neurofibromin increases rat sarcoma viral oncogene homolog (RAS) activity. This increased RAS activity causes unopposed cell growth and activation of important downstream intermediates such as the mitogen-activated protein kinase (MAPK) and the mammalian target of rapamycin (mTOR) pathways. 2, 9 Neurofibromin is also involved in the regulation of cyclic adenosine monophosphate levels, which has been shown to affect the CNS in animal models, and importantly in OPG formation.
the NF1 tumor-suppressor gene. The "second hit" in this "2-hit hypothesis" pathway is a somatic mutation, causing loss of heterozygosity of the NF1 gene, and consequently leading to Schwann cell neurofibromas along with other tumors. 9 
CLINICAL PRESENTATION
Neurofibromatosis 1 is a neurocutaneous disorder with an age-dependent, variable clinical presentation. This often leads to difficulty in establishing an early diagnosis. Despite this, NF1 has well-recognized diagnostic criteria as outlined in Table 1 . 15 Although these "classical" criteria are widely used and agreed upon, additional new cutaneous and extracutaneous features have been described in recent years (Table 1 ). An example of this is the presence of unidentified bright objects on imaging. These are seen as hyperintense lesions on T2-weighted brain magnetic resonance imaging (MRI) scans, which may represent aberrant gliosis pathognomonic of NF1. 16 Additionally, advanced molecular analysis is now available, refining our knowledge of the NF1 gene mutation. 17 A small subset of patients present with a somatic mutation or "segmental" NF1 where the clinical features only affect a specific area of the body and neither parent is affected. 18 Other phenotypic presentations in patients with an NF1 gene mutation include neurofibromatosis-Noonan syndrome, which may occur in up to 12% of these patients. Clinical features are an overlap between the 2 named syndromes and include the Noonan features of short stature, ocular hypertelorism, low-set ears, and downslanting palpebral fissures. 19 
Lisch Nodules
Austrian ophthalmologist Karl Lisch was the first to emphasize what are now called Lisch nodules and their association with NF1 in 1937. 20 Histologically Lisch nodules are melanocytic hamartomas, consisting of a condensation of spindle cells on the anterior iris surface. Stromal iris nevi underlie the pigmented nodules. 21 They are present on the anterior iris surface or in the anterior chamber angle. They are well-defined yellow-brown dome-shaped elevated lesions and can range in size from pinpoint to large (Fig. 1) . 20, 22 Although Lisch nodules do not cause ocular morbidity or disability, they are important because they are one of the diagnostic criteria for NF1. Their presence is age-dependent. Although their presence is unusual before the age of 2 years, they are seen in half of 5-year-olds, 75% of 15-year-olds, and almost 100% of adults older than 30 years. 
Skin
Café au lait macules and skin fold freckling do not usually cause complications and have no malignant potential. 23 They are an important component of the diagnostic criteria of NF1. Café au lait patches are usually the first identified clinical manifestation in NF1. 24 They are usually present within the first 2 years of life.
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They present as well-defined hyperpigmented macular lesions that are generally absent from the scalp and eyebrows along with the palms and soles (Fig. 2) . 18 Histologically these lesions are due to increased proliferation of epidermal melanocytes with basal hyperpigmentation of the epidermis.
Axillary and inguinal freckling usually presents after the development of café au lait macules by the age of 5 to 8 years. Typically, they present as small freckles less than 5 mm in size in the axillary or inguinal area. 18, 24, 25 They may also present in areas where skin folds are in apposition, including the neck and under the breasts in women. 7 These are given the eponymous name, Crowe sign, after the physician Frank Crowe who first described their association with café au lait macules in the diagnosis of NF1 in 1964. 26 
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Neurofibromas
Neurofibromas are a hallmark feature of NF1, present in almost all patients older than 30 years. 25 They are benign soft tissue tumors of Schwann cell origin that arise on peripheral nerves. 27 In addition to neoplastic Schwann cells, they also contain fibroblasts, macrophages, and mast cells. 28 Clinically, neurofibromas can be further classified as cutaneous, subcutaneous, or plexiform which can be further divided into nodular or diffuse. The features of each are outlined in Table 2 . [17] [18] [19] 24 Although they typically present symptomatically on the skin, they can also develop deep within the body and may remain largely asymptomatic.
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Like most features in NF1, the presence of neurofibromas is age-dependent. Although neurofibromas tend to increase with age, the presence of plexiform neurofibromas may manifest at birth and are most active during the first decade of life, developing in 25% to 50% of individuals with NF1. 29 The morbidity associated with plexiform neurofibromas is 2-fold. In addition to the disfigurement, bony destruction, and pain associated with these lesions, they also carry an 8% to 13% lifetime risk of malignant transformation [malignant peripheral nerve sheath tumor (MPNSTs)]. 23, 24 This rate of malignant transformation is higher than previously thought. 30 Unlike cutaneous neurofibromas, plexiform neurofibromas can infiltrate surrounding soft tissue and arise from multiple nerve fascicles, with multiple discrete tumors forming along nerve trunks. 23 Growth of these tumors is often unpredictable and is usually rapid during the first decade of life, resulting in significant disfigurement and functional impairment. 25 Palpebral plexiform neurofibromas typically affect the upper eyelid unilaterally appearing in infancy or early childhood and may result in significant functional impairment including amblyopia.
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This may be due to a mechanical ptosis causing astigmatism. As always in pediatric patients, regular refraction, dilated examination, and amblyopia treatment are of utmost importance, particularly in NF1 patients presenting with eyelid plexiform neurofibromas.
Unfortunately, MPNSTs have a poor prognosis with a 5-year survival of up to 60%, warranting ongoing careful surveillance with a low threshold for investigation. 31 Poor prognosis is Although a histological diagnosis remains the gold standard in differentiating benign from malignant lesions, imaging with positron emission tomography and computed tomography combined with a flurodeoxyglucose tracer provides a noninvasive technique to identify malignant transformation based on in-vivo glucose metabolism. 31 Definitive diagnosis of a MPNST requires pathological identification.
Neurofibroma Treatment
Plexiform neurofibromas are notoriously difficult to treat surgically due to their infiltration of adjacent normal tissue and the commonly reported risk of regrowth after excision. 33 Targeted chemotherapeutic agents such as imatinib (tyrosine kinase inhibitor) have also been studied but have only demonstrated a modest reduction in tumor volume size in a phase 2 trial in affected patients with clinically significant plexiform neurofibromas due to NF1. 34 Interferons exert antitumor activity via a number of mechanisms including antiproliferative, antiangiogenesis, and cytotoxic effects. A phase 1 trial of pegylated interferonalpha-1beta in young patients with progressive and unresectable plexiform neurofibromas has demonstrated a promising reduction and stabilization of plexiform neurofibroma size. 35 Clinical trials with biologic agents including mTOR and MAPK (MEK) inhibitors are underway. 36 Studies looking at MEK inhibitors in mouse models have demonstrated that blocking MEK signaling was sufficient to profoundly shrink existing neurofibromas. 37 Clinical trials with MEK inhibitors for plexiform neurofibromas are ongoing or in development and will allow further evaluation of the utility of the mouse model in predicting response in humans.
Although these studies have shown promising results in plexiform neurofibromas, unfortunately they have only demonstrated a transient benefit in the treatment of MPNST in mice models. 36, 38 In contrast, mTOR pathway inhibitors such as rapamycin suppress the growth of these MPNST but have not demonstrated tumor regression. 39 The mTOR pathway is critically deregulated in NF1-mutant MPNST, hence the role of mTOR inhibitors. 39 However, when combined with heat shock protein 90 inhibitors, potent tumor regression is observed. 40 
Anterior Segment and Uvea
The presence of choroidal abnormalities in neurofibromatosis was reported in as early as the 1930s. 41 These lesions were identified on enucleated specimens and attributed to proliferating Schwann cells arranged as concentric rings around axons. 42, 43 More recently, a number of case series have used confocal nearinfrared reflectance (NIR) imaging as a means of identifying these choroidal lesions in NF1 patients. [44] [45] [46] [47] In each of these studies, the choroidal abnormalities identified were not visualized by simple ophthalmoscopic examination or fundus fluorescein angiography. 46 Further studies have found that these choroidal abnormalities tend to increase with age and are particularly localized around the posterior pole.
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Near-infrared reflectance imaging at 815 nm and optical coherence tomography have further elucidated the presence of these choroidal bright patchy nodules in patients with NF1. 46 Viola et al 46 found choroidal bright patches in 82% of NF1 patients compared with only 7% of normal controls with a diagnostic sensitivity of 83% and specificity of 96%. These choroidal abnormalities have been further categorized as either "domeshaped" or "placoid-like". 48 These lesions are also reported at a high frequency in pediatric NF1 patients. 47 The appearance of these lesions on NIR imaging is demonstrated in Figure 3 .
These studies highlight the potential importance of choroidal involvement as a new diagnostic criterion for NF1. In particular, the use of NIR imaging to detect these choroidal abnormalities is gaining increasing interest particularly among ophthalmologists as a possible screening tool, as it is noninvasive and can be applied to the pediatric population, at least in older children. 46, 47 Additional choroidal changes that have also been described include a reduction in mean choroidal thickness, which may be related to altered choroidal circulation in the presence of choroidal nodules (Fig. 4) . 48 Another case report has identified increased subfoveal choroidal thickness in a case of NF1. 49 Pigmentary hamartomas (choroidal nevi) may also involve the posterior uveal tract in up to 30% of affected patients. 50 Although the association of glaucoma and neurofibromatosis has been described in the literature as a rare association, the mechanism is not well understood and is most likely related to angle closure. 25, 51, 52 A retrospective histological study by Edward et al 51 analyzed the eyes from 5 patients with NF1 and glaucoma, ranging in age from birth to 13 years. They identified endothelialization of the anterior chamber angle, which they hypothesized might be related to overexpression of the RAS-MAPK genes in these eyes. 51 Clinically, infiltration of the iris and angle with neurofibromas may obstruct the angle resulting in secondary angle closure. 25 Other anterior segment features include congenital ectropion uvea, iris heterochromia, developmental anomaly of the angle, and posterior embryotoxon, which may all predispose to glaucoma. 51 Interestingly, Morales et al 53 found ipsilateral glaucoma and increased axial length in 23% of 95 patients with orbitofacial involvement.
Skeletal Anomalies
A number of skeletal manifestations are recognized in NF1 patients. These may present as either generalized or focal bony abnormalities. Generalized bony changes include osteopenia, short stature, and macrocephaly. 36 In NF1 patients older than 40 years, a 5-fold increase in fracture risk has been reported, with a 3-fold risk in children younger than 16 years.
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Focal bony abnormalities include tibial dysplasia/ pseudarthrosis (2%), sphenoid wing dysplasia (1-6%), scoliosis (10-15%), nonossifying fibrosis, pectus deformities of the chest, and rarely, defects in the occipital bone. 24, 36, 55 Of particular significance to the ophthalmologists is the presence of sphenoid wing dysplasia that may present with asymmetric orbits, proptosis, or enophthalmos. 24 More specifically, these patients usually present with pulsatile proptosis due to herniation of the temporal lobe into the orbit. 23 Importantly, absence or thinning of the sphenoid wing may be due to the presence of an orbital plexiform neurofibroma.
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Although the mechanisms underlying these osseous manifestations remain poorly understood, studies have demonstrated that neurofibromin plays a critical role in regulating mesenchymal stem/progenitor cell differentiation into osteoblasts, affecting collagen synthesis and mineralization. 36, 56 A defect in this process is likely to contribute in part to some of these clinical features. Ideally, specialized pediatric orthopedic surgeons should manage these children.
Optic Pathway Gliomas
Optic pathway gliomas account for 5% of pediatric intracranial tumors. 57 Traditional figures suggest that 15% to 20% of children with NF1 will develop a low-grade glial neoplasm. 58, 59 A large retrospective review of 861 patients seen at the tertiary referral neurofibromatosis clinic at the Children's Hospital at Westmead in Sydney found a prevalence of 6.6% in their population. 60 Optic pathway gliomas can occur anywhere in the brain or spine in children with NF1. They are, however, most common in the optic pathway, hypothalamus, and (to a lesser extent) brainstem. 24, 61 The traditional Dodge classification (DC) of OPGs proposed in 1958 62 defines tumors anatomically as involving the optic nerves alone (stage 1), the chiasm with or without nerve involvement (stage 2), and the hypothalamus or other adjacent structures (stage 3). The DC has long been used to select patients for resection of optic nerve tumors and to provide an important indicator of prognosis with tumors at the optic chiasm having a poorer outcome. More recently, a modified DC has introduced an imaging-based method using MRI scans and is referred to as the PLAN score. 63 This updated score provides a more detailed anatomical description that can help to categorize and select tumors at a higher risk of visual morbidity to better guide treatment and detect change. Taylor et al 63 found that NF1-positive cases more commonly involved both optic nerves and multiple locations at other sites whereas NF1-negative tumors more commonly involved the central chiasm and the hypothalamus. Most patients will be diagnosed before 6 years of age, 61 although other series have found that up to 30% of children presented with OPGs after the age of 6.
60,64 Table 3 outlines the features of the most common subtype, pilocytic astrocytoma. Although pilocytic astrocytomas are common in NF1 patients and usually follow an indolent course, they may spontaneously resolve without intervention. 36, 65 Pilomyxoid astrocytoma, another subtype, is less common in the context of NF1.
2 It is found that NF1-associated OPGs have active MAPK signaling and rarely transform into high-grade tumors with no malignant potential.
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These tumors may have a wide range of clinical presentations. Many OPGs are asymptomatic. They may become evident either as a result of patient signs or symptoms or as an incidental finding on " baseline" neuroimaging studies. 66 A study by Listernick et al 67 in 1989 demonstrated that, if all children with NF1 undergo screening neuroimaging, 15% of them will have radiographic evidence of OPG with only half of these children developing symptoms or signs related to the OPG. 60, 67, 68 Symptomatic OPG in children with NF1 generally results in decreased visual acuity, diminished visual fields, abnormal pupillary function, or proptosis. It is important to note that young children rarely complain of vision loss, necessitating the use of reliable, reproducible measures to detect visual changes. 58 Reduction in visual acuity is the most common finding on screening. 61 Other less common ocular presentations include strabismus, proptosis, nystagmus, afferent pupil defect, and abnormal color vision. 61 Clinically, the optic discs usually appear pale. Low-grade glial tumors may also present with systemic manifestations such as precocious puberty or rarely, diencephalic syndrome. 68 Although it is extremely rare, the latter may occur in cases with tumor involvement of the thalamus or hypothalamus and presents with failure to thrive, vomiting, headaches, and vision abnormalities. 69 Minimum requirements for cranial MRI at diagnosis include T2-weighted, T1-weighted, and gadolinium contrast-enhanced T1-weighted sequences and fluid-attenuated inversion recovery. This is used to diagnose and monitor progression of these tumors. Typical features include fusiform enlargement, tortuosity, and kinking of the optic nerves. There may also be involvement of the chiasm (best visualized on coronal sections), optic tract, or optic radiation with diffuse enlargement. 70 Optic pathway gliomas are isointense or slightly hypointense to normal optic nerve on T1 imaging and hyperintense on T2 imaging 71, 72 (Fig. 5) . Although they may demonstrate gadolinium enhancement, not all OPGs do. Abnormal perineural tissue within the nerve sheath may also be present. 71, 72 The screening guidelines and management pathways of patients with NF1 are outlined in Figure 6 .
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Treatment
Current imaging is virtually always diagnostic, so biopsy of suspected tumors is no longer necessary. 70 Surgery is recommended for OPG cases with severe vision loss and disfiguring proptosis only when assessed by a multidisciplinary team, as surgery in NF1 OPG is rarely useful and will often sacrifice whatever vision remains. 73 A combination of carboplatin-based chemotherapy, often in conjunction with vincristine, remains the gold standard for NF1-associated low-grade gliomas requiring treatment. 74 The 5-year progression-free survival in these patients has been shown to be as high as 69%. 74 This regimen also has lower toxicity and side-effect profile than other comparable agents. 74 Other traditional chemotherapeutic agents have also been associated with a worrisome risk of secondary malignancies. 36 In recurrent, refractory tumors, alternative agents such as vinblastine have proven to be efficacious, although it is poorly tolerated due to extensive bone marrow suppression in many patients. 36 Pretreatment vision is an important prognostic indicator of final visual acuity after chemotherapy. 70 Drugs targeting tumor angiogenesis, such as bevacizumab, have shown objective responses radiologically and on vision testing in cases of refractory OPG. 75 A study by Avery et al 76 in 2014 looked at the use of intravenous bevacizumab in 4 cases of pediatric OPGs who demonstrated progressive visual acuity or visual field loss despite prior treatment with chemotherapy or proton-beam radiotherapy. All 4 subjects demonstrated a marked improvement in their visual acuity, visual field, or both while receiving bevacizumabbased therapy. 76 Although further studies are required, this presents a promising treatment in addition to standard therapies. The Pediatric Brain Tumour Consortium study is currently evaluating the use of selumetinib, an MEK inhibitor, in children with recurrent or refractory low-grade gliomas with promising results.
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Screening for Optic Pathway Tumors in NF1
One of the critical roles that ophthalmology plays in the management of children with NF1 is the regular monitoring and screening for OPGs. Given the high frequency of learning and behavioral problems in NF1 children, this regular screening should be in the context of a multidisciplinary team. 23 Routine screening remains the commonest means to identify OPGs. 61 The neuro-ophthalmic examination is a key component in the diagnosis and management of OPGs. In children with NF1, examination guidelines have been developed by expert consensus 58 and are outlined in Figure 6 . The Response Evaluation in Neurofibromatosis and Schwannomatosis Visual Outcomes Committee recommends that visual acuity should be the primary outcome measure to assess for tumor progression, guide treatment decisions, and evaluate treatment effect. 61 Pattern visual evoked potentials are performed in some centers at the same frequency as neuroimaging. These provide additional objective evidence for visual pathway dysfunction when performed in laboratories experienced with visual electrophysiology in children. Multifocal visual evoked potentials offer a method for assessing the topographic optic nerve function, providing an objective measure of visual field function. 78, 79 Optical coherence tomography of the optic nerve has also proved to be an effective, noninvasive tool to assess for progressive retinal nerve fiber layer thinning secondary to OPGs in NF1 patients; although it is not considered standard surveillance, it has proved a potential biomarker of vision in NF1 OPGs. 59, 80 The decision on when to treat children with OPGs remains controversial and relies on input from a multidisciplinary team. Treatment is reserved for progressive disease, which may include either reduced vision or radiographic tumor growth, or a combination of the 2.
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Central Nervous System and Other Systems
Other CNS Tumors
Gliomas can present throughout the CNS in individuals with NF1. 73 It is important to recognize that among patients with NF1 who are older than 10 years, the relative risk of a brain tumor is 100 times higher than those without NF1. 81 Most brain tumors in children with NF1 are low-grade gliomas [World Health Organization (WHO) grade I-II], and the majority of those are WHO grade I. 9 These tumors do have malignant potential and can infiltrate the brain. 9 Brainstem gliomas associated with NF1 have been described and, in contrast to the general population, they tend to have a more indolent course and may not require treatment. 
Non-CNS Tumors
A range of other non-CNS tumors has also been reported in patients with NF1 including pheochromocytomas, which may initially present with hypertension. 9 Gastrointestinal fibromas have also been described. 9 The lifetime breast cancer risk is 4 times higher in women with NF1 who are younger than 50 years compared with the general population. 83 Women with NF1 also have an increased risk for invasive breast cancer across all age groups. The mean full-scale intelligence quotient is in the low-toaverage range. 23 The incidence of true cognitive delay in NF1 is, however, lower than expected. 84 There are increased rates of autism spectrum disorder, attention-deficit hyperactivity, and sleep disturbances in these patients. 85 Language difficulties, particularly receptive language and language structure, have been identified as issues in children with NF1. 86 In view of these findings, early neuropsychological screening assessment to help evaluate and support these children as they enter school should be considered. 24 This also supports the need for ongoing routine screening, which is best performed in dedicated NF multidisciplinary clinics.
Vascular Complications
A number of cardiovascular abnormalities have also been described in NF1 patients. Congenital heart disease, particularly pulmonary stenosis, accounts for as many as 50% of these abnormalities. 87 Other NF1-related vascular abnormalities include renal and cerebral artery stenosis, moyamoya, aneurysmal lesions, and arteriovenous fistula malformations. 36 Interestingly, both adult and pediatric patients with NF1 have a significantly increased risk of stroke when compared with the general population. 88 Although the risk is most notable for hemorrhagic strokes, it is also increased for ischemic strokes in children due to a number of underlying vascular lesions. 88, 89 Various associations have included moyamoya arteriopathy, 90 cerebral aneurysms, and ectatic cerebral vessels. 89 
Prognosis
In children with NF1-associated OPG after chemotherapy, approximately a third will regain some vision with treatment. 91 Unlike vision, which will largely remain stable or may even improve, NF1 reduces average life expectancy by 10 to 15 years, and malignant tumors are the most common cause of death in individuals with this syndrome. 7 It is important to remember that NF1 patients have a 5-fold risk for cancer and more than a 2000-fold risk for neurogenic malignancies compared with the general population. 92 
CONCLUSIONS
As NF1 remains a multisystem disease with life-threatening complications, a multidisciplinary approach with close collaboration among NF1 clinicians will facilitate a uniform method for diagnosis and management of this condition. Ophthalmologists have a crucial role in diagnosis and in monitoring visual function. The recent characterization of the choroidal hamartomas emphasizes this role.
Despite the recent and exciting new advances in NF1 research, including MEK and mTOR inhibitors, there still remain many questions about the disease. The continuing challenge for clinicians is the detection of progression of OPG as early as possible so that effective treatment can be instigated to maximize the preservation of vision.
